Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cancer prevalence among COVID-19 patients may be higher than previously reported

Key clinical point: While an early report pegged the prevalence of cancer among COVID-19 patients at 1%, a recent meta-analysis came up with higher numbers, which are nevertheless still inconclusive because of limitations of the underlying data.

Major finding: The pooled prevalence of cancer was 2.0% (95% confidence interval, 2.0-3.0%) overall and 3.0% (95% CI, 1.0-6.0%) in studies with sample sizes under 100 individuals.

Study details: A meta-analysis of 11 studies including 3,661 COVID-19 cases.

Disclosures: The study authors reported no potential conflicts of interest.


Desai A et al. JCO Glob Oncol. 2020 Apr 6. doi: 10.1200/GO.20.00097.